11.1 USP <795> Non-Sterile Compounding & NJ Standards

11.1 USP <795> Non-Sterile Compounding & NJ Standards

Non-sterile pharmaceutical compounding is a foundational discipline within pharmacy practice, enabling pharmacists to tailor personalized drug therapies when commercially manufactured products cannot meet a patient's individual clinical needs. In New Jersey, non-sterile compounding is governed jointly by the United States Pharmacopeia (USP) General Chapter <795> (Pharmaceutical Compounding – Nonsterile Preparations), the federal Food, Drug, and Cosmetic Act (FD&C Act), and the New Jersey State Board of Pharmacy administrative regulations codified at N.J.A.C. 13:39-11.

Candidates preparing for the New Jersey Multistate Pharmacy Jurisprudence Examination (NJ MPJE) must master the legal boundary between traditional pharmacy compounding and commercial drug manufacturing, the procedural tiers of non-sterile compounding, the strict parameters governing Beyond-Use Dates (BUDs), and the rigorous documentation standards mandated under New Jersey law.

---

Regulatory Framework: 503A Traditional Pharmacies vs. 503B Outsourcing Facilities

The modern regulatory architecture governing compounding was codified by Congress in the Drug Quality and Security Act (DQSA) of 2013, which clarified the distinctions under the FD&C Act between traditional state-regulated compounding pharmacies and commercial compounding manufacturers.

                                  Compounding Entities
                                           │
         ┌─────────────────────────────────┴─────────────────────────────────┐
         ▼                                                                   ▼
Section 503A Traditional Pharmacy                               Section 503B Outsourcing Facility
• Patient-specific prescriptions                                • Batch compounding (no Rx required upfront)
• State Board of Pharmacy oversight                             • FDA oversight & mandatory registration
• Exempt from cGMP (USP <795>/<797>)                            • Full compliance with cGMP (21 CFR 210/211)
• Exempt from FDA premarket approval                            • Exempt from FDA premarket approval
• Limited anticipatory compounding permitted                    • Mandatory adverse event reporting (15 days)

Section 503A: Traditional State-Licensed Compounding Pharmacies

Under Section 503A of the FD&C Act (21 U.S.C. § 353a):

• Patient-Specific Mandate: Compounding must occur pursuant to a valid, patient-specific prescription order from a licensed practitioner, or in limited quantities before the receipt of a prescription order (anticipatory compounding) based on an established history of receiving valid prescriptions generated by an established relationship between the pharmacist, patient, and prescriber.
• Statutory Exemptions: Section 503A pharmacies are explicitly exempt from three major federal statutory requirements applicable to drug manufacturers:
  1. Compliance with current Good Manufacturing Practice (cGMP) regulations under 21 U.S.C. § 351(a)(2)(B);
  2. Labeling with adequate directions for use under 21 U.S.C. § 352(f)(1); and
  3. FDA new drug premarket approval requirements under 21 U.S.C. § 355.
• Regulatory Oversight: Section 503A facilities are primarily licensed, inspected, and regulated by the New Jersey State Board of Pharmacy and must comply with official USP standards (<795>, <797>, and <800>) as adopted by N.J.A.C. 13:39-11.
• Copies of Commercial Products: Pharmacists are strictly prohibited from compounding preparations that are essentially copies of commercially available, FDA-approved drug products on a regular or inordinate basis. Compounding a commercially available product is permissible only when there is a documented change that produces a significant clinical difference for an individual patient (e.g., removing an allergic dye or excipient, or converting an oral solid tablet into an oral liquid for a patient with dysphagia), and such justification is documented on the prescription order.

Section 503B: Registered Outsourcing Facilities

Under Section 503B of the FD&C Act (21 U.S.C. § 353b):

• Voluntary Federal Registration: A compounding facility may elect to register with the FDA as an outsourcing facility.
• Batch Compounding Without Prescriptions: 503B facilities are permitted to engage in large-scale sterile and non-sterile compounding and distribute compounded preparations in batches to healthcare facilities, clinics, and hospitals without requiring patient-specific prescriptions.
• cGMP Mandate: 503B facilities are NOT exempt from cGMP. They must comply with rigorous federal cGMP regulations (21 CFR Parts 210 and 211), including validated sterilization cycles, environmental monitoring, stability testing, and batch release criteria.
• Direct FDA Oversight: Outsourcing facilities are subject to direct FDA inspection on a risk-based schedule, must pay annual federal establishment registration fees, submit bi-annual drug compounding reports to the FDA, and report all serious adverse drug events to the FDA within 15 calendar days.

---

Categories of Non-Sterile Compounding Under Updated USP <795>

USP General Chapter <795> categorizes non-sterile compounding into three distinct procedural tiers based on the complexity of the formulation, the availability of validated stability data, and the nature of the manipulations required.

1. Simple Compounding

Simple compounding involves making a preparation that has an official USP compounding monograph (e.g., Captopril Oral Solution USP, Baclofen Oral Suspension USP) or that appears in a peer-reviewed scientific journal article that explicitly details components, compounding procedures, quantities, and stability data. It also encompasses the reconstitution or manipulation of commercial products that require the addition of one or more manufactured commercial products as directed by the manufacturer (e.g., combining two commercial topical ointments or creams in equal ratios).

2. Moderate Compounding

Moderate compounding encompasses preparations that require special calculations or procedures to determine the quantities of components per preparation or per individualized dosage unit (e.g., calibrating a mold to determine the displacement volume of a suppository base or troche base). Moderate compounding also includes formulations for which peer-reviewed stability data for that specific formulation is not available (e.g., combining two or more manufactured drug products when the chemical stability of the resulting mixture is unknown).

3. Complex Compounding

Complex compounding requires specialized training, specialized facilities, advanced equipment, or complex operational procedures to ensure appropriate clinical outcomes. Examples include:

• Compounding modified-release dosage forms (e.g., controlled-release capsules);
• Compounding transdermal delivery dosage forms (e.g., liposomal delivery creams or pluronic lecithin organogel [PLO] formulations intended for systemic transdermal absorption);
• Compounding innovative dosage forms or delivery systems where therapeutic failure or toxicity could result from minor deviations in particle size or uniform dispersion.

---

Beyond-Use Dating (BUD) Hierarchy Under USP <795>

A Beyond-Use Date (BUD) is the date and time after which a compounded preparation must not be used, administered, or stored. Unlike commercial drug expiration dates, which are determined through multi-year industrial stability studies under varying environmental stressors, BUDs are assigned conservatively to ensure chemical and physical stability as well as microbiological integrity.

[!IMPORTANT] The Shortest Component Expiration Rule: Under USP <795>, the assigned BUD can NEVER exceed the shortest expiration date of any starting active pharmaceutical ingredient (API) or manufactured component used in the preparation. If an oral liquid is compounded using an ingredient that expires in 10 days, the BUD cannot exceed 10 days, regardless of the default limits.

Default Beyond-Use Dates in the Absence of Stability Studies

When a compounded non-sterile preparation (CNSP) is prepared without specific, validated stability-indicating analytical studies, the compounder must adhere strictly to the default BUD limits established by updated USP <795>. These limits are categorized by dosage form and water activity (aw):

                                    USP <795> Default BUDs
                                              │
         ┌────────────────────────────────────┼────────────────────────────────────┐
         ▼                                    ▼                                    ▼
Non-Preserved Aqueous                 Preserved Aqueous                    Non-Aqueous Forms
• Water activity aw ≥ 0.60           • Water activity aw ≥ 0.60           • Water activity aw < 0.60
• Oral solutions / suspensions       • Creams, gels, preserved liquids    • Capsules, tablets, ointments
• BUD: 14 Days                       • BUD: 35 Days                       • Oral/Mucosal: 90 Days
• Storage: REFRIGERATED ONLY         • Storage: Room Temp or Fridge       • Topical/Anhydrous: 180 Days
  (2°C to 8°C [36°F to 46°F])          (20°C-25°C or 2°C-8°C)             • Storage: Room Temp or Fridge

1. Non-Preserved Aqueous Dosage Forms

• Definition: Formulations containing water (water activity aw ≥ 0.60) that do not contain an effective antimicrobial preservative system. Common examples include non-preserved oral solutions, oral suspensions, and oral emulsions.
• Maximum Allowable BUD: 14 days.
• Mandatory Storage Condition: Must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Controlled room temperature storage is strictly prohibited for non-preserved aqueous oral preparations.

2. Preserved Aqueous Dosage Forms

• Definition: Formulations containing water (water activity aw ≥ 0.60) that incorporate an effective antimicrobial preservative agent (e.g., parabens, sodium benzoate, sorbic acid) or have inherent antimicrobial properties, such as topical creams, topical emulsions, topical gels, and preserved aqueous oral liquids.
• Maximum Allowable BUD: 35 days.
• Storage Condition: Controlled room temperature (20°C to 25°C [68°F to 77°F]) or refrigerated (2°C to 8°C [36°F to 46°F]).

3. Non-Aqueous Dosage Forms (aw < 0.60)

• Oral and Mucosal Non-Aqueous Dosage Forms: Formulations with low water activity designed for oral or mucosal administration, such as capsules, powders, tablets, troches, and non-aqueous oral liquids (e.g., active ingredients dissolved in fixed vegetable oils or polyethylene glycol [PEG]).
  • Maximum Allowable BUD: 90 days at controlled room temperature or refrigerated.
• Topical, Dermal, and Non-Aqueous Solid/Liquid Dosage Forms: Anhydrous formulations applied topically, such as anhydrous ointments (e.g., White Petrolatum or Aquaphor bases), suppositories, anhydrous pastes, and non-aqueous topical suspensions.
  • Maximum Allowable BUD: 180 days at controlled room temperature or refrigerated.

Extending BUDs Beyond Default Limits

A compounder may assign an extended BUD exceeding the default limits only if the extended dating is supported by a valid stability-indicating assay published in peer-reviewed scientific literature or directly performed on the specific formulation, container-closure system, and storage conditions. Furthermore, for aqueous formulations, the preparation must pass USP <51> Antimicrobial Effectiveness Testing to ensure microbiological stability over the extended period.

---

Master Formulation Record (MFR) vs. Compounding Record (CR)

USP <795> and N.J.A.C. 13:39-11 establish a strict distinction between the overarching formulation recipe and the lot-specific preparation log. Both documents are mandatory.

Master Formulation Record (MFR) — The Recipe Blueprint

The Master Formulation Record represents the permanent, authorized recipe that provides the instructions for preparing the compounded preparation. Under USP <795>, an MFR must be created for each unique non-sterile preparation prepared for more than one patient, or whenever compounding from non-sterile raw bulk substances.

• Mandatory Contents of an MFR:
  • Official or assigned name, strength, and dosage form of the preparation;
  • Master list of all active pharmaceutical ingredients and excipients, including specific chemical grades and exact quantities;
  • Complete equipment required to compound the preparation (e.g., analytical balance, glass mortar, specific sieve size);
  • Specific compounding procedures, including mixing order, heating requirements, and duration;
  • Container-closure system specifications (e.g., amber glass bottle with child-resistant closure);
  • Assigned default BUD and the scientific rationale or literature citation supporting it;
  • Detailed storage conditions (e.g., protect from light, refrigerate at 2°C to 8°C);
  • Physical description of the finished preparation (e.g., white, opaque, viscous suspension with cherry odor);
  • Explicit quality control (QC) testing procedures and acceptance criteria (e.g., pH range 5.0 to 5.5, weight variation limits, visual uniformity).

Compounding Record (CR) — The Batch Execution Log

The Compounding Record is the operational document generated each time a specific batch or individual prescription of a compounded preparation is prepared. It captures the actual execution of the compounding process.

• Mandatory Contents of a CR:
  • Official or assigned name, strength, and dosage form;
  • Direct cross-reference to the corresponding Master Formulation Record (MFR);
  • Specific names, manufacturers, commercial lot numbers, and expiration dates of all components used;
  • Actual weights and volumetric measurements recorded during compounding;
  • Total quantity compounded (e.g., 100 capsules or 240 mL);
  • Unique internal lot or control number assigned to the specific preparation;
  • Assigned Beyond-Use Date (BUD) and specific storage requirements;
  • Results of quality control evaluation (e.g., observed pH, visual appearance, capsule fill uniformity);
  • Date and time the preparation was compounded;
  • Initials or signatures of the individual who compounded the preparation (e.g., pharmacy technician or intern) and the supervising licensed pharmacist who verified the compound.

[!WARNING] Common Board Inspection Citation: Board inspectors frequently cite pharmacies for failing to document the manufacturer lot numbers and expiration dates of inactive excipients (such as suspending vehicles, flavorings, or capsule shell lots) on the Compounding Record. Under New Jersey law, every single component—both active and inactive—must be fully traceable.

---

Facility Standards, Equipment Calibration & Operational Controls

Under N.J.A.C. 13:39-11 and USP <795>, the pharmacy practice site must provide a dedicated compounding environment that prevents contamination and cross-contamination:

Compounding Space & Plumbing

• Compounding must occur in a dedicated, clean space separated from routine dispensing workflows, with adequate lighting and ventilation.
• The compounding area must feature smooth, non-porous surfaces (countertops, walls, shelving) that are impervious to chemical sanitizers and easy to clean.
• A sink with hot and cold potable water, soap, and single-use disposable towels or an electric air hand dryer must be accessible within the compounding space. Purified water (USP grade) must be utilized for compounding formulations and for final rinsing of compounding equipment.

Equipment Calibration and Verification

• All measuring, weighing, and mechanical equipment (e.g., Class A prescription balances, analytical electronic balances, pH meters, hot plates, ointment mills) must be inspected, calibrated, and certified at regular intervals according to the manufacturer's operational manual.
• Electronic balances must be verified using calibrated standard weights prior to first use each day or immediately prior to compounding.
• Written maintenance, calibration, and cleaning logs must be maintained for each piece of equipment, documenting the date, calibration results, service technician identification, and supervising pharmacist verification.

---

Personnel Training, Competency & New Jersey 5-Year Record Retention

Compounding personnel represent the primary vector of errors and contamination in pharmaceutical compounding. New Jersey rules enforce strict ongoing oversight:

Training and Competency Assessment

• Before being permitted to compound non-sterile preparations, all personnel (pharmacists, pharmacy technicians, and pharmacy interns) must complete comprehensive training and successfully demonstrate competency in:
  • Hand hygiene and garbing procedures;
  • Proper use and calibration of equipment;
  • Accurate calculation, weighing, and measuring of components;
  • Aseptic manipulation and physical mixing techniques;
  • MFR and CR documentation protocols;
  • Packaging, labeling, and storage rules.
• Annual Competency Frequency: Core competencies must be evaluated and documented at least annually for all personnel involved in non-sterile compounding.

New Jersey 5-Year Record Retention Standard

Under N.J.A.C. 13:39-11.2, all records relating to non-sterile compounding must be maintained for a minimum of five (5) years from the date of compounding. This 5-year retention mandate applies to:

• Master Formulation Records (MFRs);
• Lot-specific Compounding Records (CRs);
• Equipment cleaning, maintenance, and calibration logs;
• Certificates of Analysis (COAs) for all bulk active pharmaceutical ingredients;
• Personnel training and annual competency evaluation documentation.

All records must be maintained on-site at the licensed pharmacy practice site and made immediately retrievable upon request by authorized inspectors of the New Jersey State Board of Pharmacy or the Division of Consumer Affairs.

---

Clinical & Legal Case Scenario: Navigating BUD and Component Expiration

Scenario: On September 6, 2026, a New Jersey community pharmacist receives a prescription for 120 mL of an oral suspension of Spironolactone 5 mg/mL for an 8-year-old pediatric patient with congenital heart failure. There is no commercial liquid available. The pharmacist refers to a verified Master Formulation Record that combines Spironolactone powder with an aqueous, non-preserved vehicle containing purified water, flavoring, and xanthan gum. The Spironolactone powder bottle has a manufacturer expiration date of June 2028. However, the commercial xanthan gum excipient opened by the technician expires on September 16, 2026.

Legal & Clinical Analysis:

1. Dosage Form Classification: The preparation is an aqueous oral suspension without an effective antimicrobial preservative system (aw ≥ 0.60).
2. Default Baseline BUD: Under updated USP <795>, the default BUD for a non-preserved aqueous oral liquid is 14 days refrigerated (2°C to 8°C), which would correspond to September 20, 2026.
3. Component Expiration Override: The xanthan gum excipient expires on September 16, 2026 (10 days from compounding). Because the BUD can never exceed the shortest expiration date of any starting component, the maximum legal BUD that can be assigned is September 16, 2026 (10 days).
4. Storage Mandate: The auxiliary label must state: "Keep Refrigerated (2°C to 8°C / 36°F to 46°F). Shake Well Before Use."
5. Documentation & Retention: The pharmacist must record the lot numbers and expiration dates of both the active drug and the xanthan gum on the Compounding Record, sign the verification block, and retain the record for at least 5 years under N.J.A.C. 13:39-11.